(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 December 2018 (06.12.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/220040 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61K 31/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2018/064229

(22) International Filing Date:
30 May 2018 (30.05.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
17173712.5 31 May 2017 (31.05.2017) EP

(71) Applicant: **MORPHOSYS AG** [DE/DE]; Semmelweisstrasse 7, 82152 Planegg (DE).

(72) Inventors: **KELEMEN, Peter**; MorphoSys AG, Semmelweisstr. 7, 82152 Planegg (DE). **SCHWARZ, Michael**; MorphoSys AG, Semmelweisstr. 7, 82152 Planegg (DE). **WINDERLICH, Mark**; MorphoSys AG, Semmelweisstr. 7, 82152 Planegg (DE). **HEEGER, Steffen**; Richard-Wagner Straße 56, 68165 Mannheim (DE). **WEINELT, Dominika**; MorphoSys AG, Semmelweisstr. 7, 82152 Planegg (DE).

(74) Agent: **SPILLER, Stephan**; Semmelweisstr. 7, 82152 Planegg (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2018/220040 A1

(54) Title: TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT

Figure 1



(57) Abstract: The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.